Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Molecular, Cytological Features and Genetic Susceptibility of Occupational Chronic Obstructive Pulmonary Disease Attributable to Different Environmental Exposures
The objective of this study is to investigate molecular, cytological and genetic features of occupational chronic obstructive pulmonary disease (COPD) in conditions of different occupational exposures. In order to achieve this goal serum pro-inflammatory cytokines and standard inflammation markers level, hemostasis, cytological analysis of bronchoalveolar lavage and associations of single nucleotide polymorphisms (SNPs) rs1800470 transforming growing factor β1 (TGF β1) gene, rs1828591 hedgehog interacting protein (HHIP) gene, rs4129267 interleukin 6 receptor (IL-6R) gene, rs1051730 nicotinic acetylcholine receptor 3 (CHRNA3) gene with COPD in subjects exposed to silica dust and in those exposed to polycyclic aromatic hydrocarbons exhaust will be investigated. The relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by C-reactive protein (hsCRP) and tumor necrosis factor-α (TNF α) serum concentration, in different occupational COPD groups will be studied. The hypothesis is that the mechanisms underlying disease development and progression are different due to environmental risk factor that reflex in differs in disease attributes - molecular biomarkers, cytology results and genetic susceptibility between COPD due to dust, COPD due to chemicals and COPD in smokers therefore COPD can be subdivided into ecological phenotypes according to environmental risk factor.
Status | Completed |
Enrollment | 352 |
Est. completion date | September 2014 |
Est. primary completion date | September 2014 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | 40 Years to 75 Years |
Eligibility |
Inclusion Criteria: - Post- bronchodilator forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) ratio less than 0.7 - Stable phase of COPD - History of exposure to respirable silica dust, nonsmokers with absence of passive exposure to tobacco smoke or history of exposure to polycyclic aromatic hydrocarbons exhaust, nonsmokers with absence of passive exposure to tobacco smoke or current tobacco smokers without history of occupational exposure - COPD risk factor exposure (occupational or tobacco smoke) duration not less than 12 months - Male - Caucasian - Age of 40 - 75 years old - Control group - healthy people Exclusion Criteria: - history of biomass smoke exposure - age less than 40 and above 75 years old - current COPD exacerbation - concomitant asthma - tuberculosis and other pulmonary diseases - allergic and autoimmune disorders - active infections - immunodeficiency, including HIV infection - parasitological diseases - malignancies - lack of informed consent |
Observational Model: Case Control, Time Perspective: Cross-Sectional
Country | Name | City | State |
---|---|---|---|
Russian Federation | Novosibirsk City Hospital #2 | Novosibirsk |
Lead Sponsor | Collaborator |
---|---|
Novosibirsk City Hospital #2 | Siberian Branch of the Russian Academy of Medical Sciences |
Russian Federation,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Association of SNPs rs1800470 TGF ß1 gene, rs1828591 HHIP gene, rs4129267 IL-6R gene, rs1051730 CHRNA3 gene with COPD in subjects exposed to dust and in those exposed to chemicals. | Odds ratio and 95% confidence interval will be calculated for each occupational group. Controls - healthy people. | 1 day (a single measurement) | No |
Primary | Difference in cytological analysis of bronchoalveolar lavage fluid results between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in serum interleukin 1 beta (IL-1ß) level between COPD patients exposed to dust, chemicals and tobacco smoke. | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in serum TNFa level between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in spontaneous thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in collagen induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in epinephrine induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in adenosine diphosphate induced thrombocyte aggregation between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in fibrinogen level between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in fibrinogen degradation products level between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in D-dimer level between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in serum endothelin1 level between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Primary | Difference in serum nitric oxide level between COPD patients exposed to dust, chemicals and tobacco smoke | Comparison of groups. | 1 day (a single measurement) | No |
Secondary | Relationship between genotype and phenotype characteristics, such as an inflammation activity, assessed by hsCRP and TNF a serum concentration, in different occupational COPD groups. | For SNPs that will occur associated with occupational COPD differences in hsCRP and TNFa serum concentration between subjects with different genotypes will be established separately for exposed to dust COPD group and for exposed to chemicals COPD group. | 1 day (a single measurement) | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|